Saturday, June 15, 2013

Food Supplement Linked to Lower PSA in Prostate Cancer

CHICAGO, Illinois — A commercially available food supplement that contains pomegranate, broccoli, green tea, and turmeric significantly lowers prostate-specific antigen (PSA) levels, compared with placebo, in patients with prostate cancer, a double-blind placebo-controlled randomized trial has shown.

The study results, presented here at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO®), made headlines around the world and caused the polyphenol-rich supplement, known as Pomi-T (nature Medical Products), to sell out within hours.

This is a "promising new therapy," said Tomasz Beer, MD, professor of medicine and director of the prostate cancer research program at the Oregon Health and Science University in Portland, during a "highlights of the day" session.

Read the full Medscape report
(Free sign-up may be required)

Vegetable fats tied to less prostate cancer spread


(Reuters Health) - After being diagnosed with prostate cancer, men who eat a diet high in vegetable fats, such as those in nuts and olive oil, may be less likely to have their disease spread, a new study suggests.

Researchers found that replacing some carbohydrates with those healthy fats was also tied to a lower risk of dying from any cause during the study. But the opposite was true for saturated and trans fats often found in meat and processed foods.

Read the full Reuters Health report

Wednesday, May 15, 2013

Agent Orange tied to aggressive prostate cancer risk

(Reuters Health) - Men who were exposed to Agent Orange chemicals used during the Vietnam War are at higher risk for life-threatening prostate cancer than unexposed veterans, researchers have found.


What's more, those who served where the herbicide was used were diagnosed with cancer about five years earlier than other men, on average, in the new study.

"This is a very, very strong predictor of lethal cancer," said urologist Dr. Mark Garzotto, who worked on the study at the Portland Veterans Affairs Medical Center in Oregon.

Read the full Reuters Health report

Gene Test for Prostate Cancer Shows Promise

Medscape. May 08, 2013

SAN DIEGO, California — A genetic test can predict the aggressiveness of prostate cancer, a new study shows.
The 17-gene test predicts whether tumors will progress to high-grade or postsurgical stage III disease.

"We think this will allow patients and doctors to make more confident decisions," study coauthor Eric Klein, MD, told Medscape Medical News. "That will be a boon to everyone and it will save the system money."

The results of the study were presented here at the American Urological Association 2013 Annual Scientific Meeting.

Read the full Medscape report
(Free sign-up may be required)

New AUA Guideline for Castration-Resistant Prostate Cancer

Medscape. May 09, 2013

The American Urological Association (AUA) has issued a new guideline for the management of castration-resistant prostate cancer (CRPC) that provides a "rational basis" for treatment decisions.

Those decisions are now "complex" because a group of treatment options for metastatic disease has emerged in a short period of time, according to a press release issued at AUA 2013 Annual Scientific Meeting, held in San Diego, California.

Read the full Medscape report
(Free sign-up may be required)

Testosterone Benefits Hypogonadal Men With Type 2 Diabetes

Medscape. May 08, 2013.

PHOENIX — Testosterone replacement reverses insulin resistance in hypogonadal men with type 2 diabetes, preliminary data suggest. The findings, from a randomized trial in 81 men, were reported by Paresh Dandona, MD, PhD, head of the division of endocrinology, diabetes, and metabolism at the University of Buffalo, State University of New York, at the American Association of Clinical Endocrinologists 2013 Scientific & Clinical Congress last week.
"Hypogonadotropic hypogonadism [HH] in type 2 diabetes is a factor related to insulin resistance and may be contributing to it. Administration of testosterone over a period of 6 months largely reverses that state of insulin resistance," said Dr. Dandona.

Read the full Medscape report
(Free sign-up may be required)

AUA Issues New Guidelines on PSA Screening

Medscape. May 03, 2013

New guidelines on prostate cancer screening, issued today by the American Urological Association (AUA), are supportive of routine use of the prostate-specific antigen (PSA) test in healthy men, but only for a specified age group, and only after discussion between a man and his physician.

 Specifically, the new guidelines state that men 55 to 69 years of age who are at average risk and asymptomatic can consider PSA screening. They should speak to the their physician about the benefits and harms of testing to determine the best course of action.

Read the full Medscape report
(free sign-up may be required)